Estimated domestic launch time of entrectinib

Entrectinib (Entrectinib) is an oral small molecule targeted drug developed by Roche. It is mainly used to treat patients with solid tumors carrying NTRK gene fusions, ROS1 positivity or ALK rearrangements. It has shown good efficacy in the control of brain metastases, especially. The drug was approved by the US FDA as early as 2019, becoming one of the first precision treatment drugs with "tissue-independent" indications. Therapeutic strategies targeting tumor gene driver mutations have received great attention in recent years, and it is against this background that entrectinib has been rapidly promoted to many places around the world.

In the Chinese market, the introduction of entrectinib has also made important progress. Roche has completed the registration of entrectinib capsule dosage form in China and obtained formal approval from the State Food and Drug Administration for the treatment of ROS1-positive non-small cell lung cancer (NSCLC) and NTRK fusion-positive solid tumors. According to public information, entrectinib has been officially launched in China under the trade name "Rozlytrek", becoming one of the few "tissue-independent" precision treatment drugs to enter the Chinese market. The medicine is sold in capsule form, and common specifications include 100 mg with 30 capsules and 200 mg with 90 capsules, which is convenient for long-term medication management.

What is more noteworthy is that entrectinib has been included in China's national medical insurance directory. This favorable policy has greatly reduced the financial burden on patients, making it no longer a costly "self-funded targeted drug", but an affordable and sustainable treatment option. Eligible patients, especially those with intermediate and advanced tumors confirmed to be ROS1 or NTRK fusion positive by NGS or other molecular testing, can be reimbursed for relevant expenses under the framework of the medical insurance policy, which greatly improves clinical accessibility.

In terms of clinical application, doctors are also paying more attention to the screening of patients carryingNTRK fusions and ROS1 rearrangements, which will further promote the precise application of entrectinib in lung cancer, sarcoma, children's tumors and other fields.

Reference materials:https://www.roche.com/products/rozlytrek